AEMD Stock News & Analysis | Latest Updates

Aethlon Medical Announces Pricing of $4.5 Million Public Offering

(NASDAQ:AEMD) SAN DIEGO, Sept. 4, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an...

September 4, 2025Financing

AEMD News

Aethlon Medical Announces Pricing of $4.5 Million Public Offering

Aethlon Medical Has Been Granted European Patent Number EP4136453 Titled LECTIN FOR USE IN METHODS FOR TREATING A SEQUELA OF CORONAVIRUS INFECTION

World Health Organization Says MPOX Remains A Public Health Emergency Of International Concern

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Aethlon Medical Announces Poster Presentation At Keystone Symposium On Long COVID And Other Post-Acute Infection Syndromes; Presentation Reviews Hemopurifier Affinity Resin's Ability To Bind Extracellular Vesicles In Long COVID Samples

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Aethlon Medical Publishes Preclinical Data Showing Ability Of Hemopurifier To Remove Platelet-Derived Extracellular Vesicles From Plasma

Watching Aethlon Medical; Traders Circulate Article From bioRxiv: Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin (Aethlon Medical's Hemopurifier)

HC Wainwright & Co. Reiterates Buy on Aethlon Medical, Maintains $7 Price Target

Aethlon Medical Publishes Preclinical Data On The Hemopurifier In Transplant Immunology Journal Entitled, A Lectin Affinity Plasmapheresis Device Removes Extracellular Vesicles And MicroRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming

HC Wainwright & Co. Reiterates Buy on Aethlon Medical, Maintains $7 Price Target

Aethlon Medical Q3 EPS $(0.13) Beats $(0.20) Estimate

12 Health Care Stocks Moving In Friday's Pre-Market Session

Aethlon Medical Highlights Hemopurifier's 99% In Vitro Capture Of H5N1 Bird Flu Virus, Showcasing Potential For Treating Severe Infections Amid Rising Cases And Emergency Declarations In The U.S.

US Stocks Higher, Micron Reports Downbeat Sales

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

HC Wainwright & Co. Reiterates Buy on Aethlon Medical, Maintains $7 Price Target

'UK detects two more cases of new mpox variant' - Reuters

'Los Angeles Is Investigating The Death Of A Person Who Had Monkeypox' - CNBC

Aethlon Medical Publishes In Vitro Studies Demonstrating Hemopurifier Resin Binding Of 7 Clinically Relevant COVID-19 Variants